Mutation of NPM1 and FLT3 Genes in Acute Myeloid Leukemia and Their Association with Clinical and Immunophenotypic Features

Table 3

Immunophenotypic characteristics of AML patients with NPM1 and FLT3/ITD mutations.

Antigen marker	Total (161)	No mutation (100)	NPM1 (34)	FLT3/ITD (35)	NPM1 + FLT3 (13)
CD3	3%	4%	0%	0%	0%
CD5	3%	4%	0%	0%	0%
CD7	17%	14%	9%	33%*	11%
CD10	8%	11%	3%	0%	0%
CD13^#	86%	90%	71%	94%	100%
CD14	20%	22%	18%	15%	22%
CD19	22%	29%	12%	12%	8%
CD33	88%	85%	94%	94%	100%
CD34	60%	70%	29%*	61%	38%*
MPO^#	67%	67%	77%	56%	60%
HLA-DR^#	71%	81%	29%*	81%	60%
TdT^#	10%	12%	0 %	11%	0%

P values were obtained on comparing each of FLT3, NPM1, and FLT3 + NPM1 mutation groups with the no mutation group (column 2). Numbers in the table represent the percentage of positive cases for that antigen marker. *Significant P-value <0.05. ^#Markers not done in all cases.